Development and characterisation of a panel of phosphatidylinositide 3-kinase – mammalian target of rapamycin inhibitor resistant lung cancer cell lines
Abstract The PI3K-mTOR pathway is involved in regulating all hallmarks of cancer, and is often dysregulated in NSCLC, making it an attractive therapeutic target in this setting. Acquired resistance to PI3K-mTOR inhibition is a major hurdle to overcome in the success of PI3K-mTOR targeted agents. H46...
Guardado en:
Autores principales: | Susan Heavey, Paul Dowling, Gillian Moore, Martin P. Barr, Niamh Kelly, Stephen G. Maher, Sinead Cuffe, Stephen P. Finn, Kenneth J. O’Byrne, Kathy Gately |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a8ae152a78804d6da7975d71e4a44b98 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Selective binding of a toxin and phosphatidylinositides to a mammalian potassium channel
por: Yang Liu, et al.
Publicado: (2019) -
SIRT1 negatively regulates the mammalian target of rapamycin.
por: Hiyaa Singhee Ghosh, et al.
Publicado: (2010) -
Inhibiting the Mammalian Target of Rapamycin Blocks the Development of Experimental Cerebral Malaria
por: Emile B. Gordon, et al.
Publicado: (2015) -
Prognostic significance and function of mammalian target of rapamycin in tongue squamous cell carcinoma
por: Shau-Hsuan Li, et al.
Publicado: (2017) -
Blocking mammalian target of rapamycin (mTOR) improves neuropathic pain evoked by spinal cord injury
por: Wang Xiaoping, et al.
Publicado: (2016)